DOAC Works in Cancer-Related VTE, No Tradeoff in Bleeds

<![CDATA[]]>(MedPage Today) — The direct oral anticoagulant (DOAC) apixaban (Eliquis) was as good as the low molecular weight heparin dalteparin (Fragmin) for the treatment of patients with cancer-associated thrombosis — with no increase in risk of major…

Source link

Related posts

IBD Associated With Increased Risk of Parkinson’s Disease


For the first time, more women than men are in medical school


New HCV genotype subtypes present in sub-Saharan Africa


This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy


COVID-19 (Coronavirus) is a new illness that is having a major effect on all businesses globally LIVE COVID-19 STATISTICS FOR World